FIG. 2.

ANKRA2 can substitute functionally for RFXANK. (A) Schematic representations of RFXANK, ANKRA2, and the chimeric fusion constructs used to complement the BLS-1 (RFXANK^−/−) cell line. (B). Stable transfectants were analyzed by FACS for HLA-DR cell surface expression as in Fig. 1. (C) Steady-state mRNA levels for ANKRA2 were determined by quantitative real-time reverse transcription-PCR for wild-type (wt) B cells, RFXANK^−/− cells, RFXANK^−/− cells complemented with cDNA for RFXANK, and RFXANK^−/− cells complemented with cDNA for ANKRA2. The error bars indicate standard deviations. (D) Protein levels of RFXANK (in total extracts from RFXANK^−/− cells, wild-type cells, and RFXANK^−/− cells complemented with RFXANK) and the RFXANK-ANKRA2 fusion protein (in extracts from RFXANK^−/− cells complemented with the CHI1 fusion) were determined by Western blotting. The level of TATA-binding protein (TBP) was used as a loading control.